On Friday, Shares of Pandora Media, Inc. (NYSE:P), surged 14.99% to $15.96.
Pandora Media declared financial results for the second quarter ended June 30, 2015.
“Our advertising investments, particularly in local, are paying off. This quarter, local ad revenue reached an all-time high, driving record RPMs,” stated Brian McAndrews Chairman and CEO of Pandora. “Our monetization success allows us to be an even more effective platform for assisting artists grow their careers. In addition to our ability to provide insights to the entire music industry, we fuel promotion that is extremely valuable to music makers.”
Third Quarter 2015 Guidance:
Revenue is predictable to be in the range of $310 million to $315 million. Adjusted EBITDA is predictable to be in the range of $25 million to $30 million. Adjusted EBITDA excludes forecasted stock-based compensation expense of about $30 million and forecasted depreciation and amortization expense of about $6 million and assumes minimal provision for income taxes given our net loss position. Diluted shares outstanding for the third quarter 2015 are predictable to be about 222 million.
Full Year 2015 Guidance:
Revenue is predictable to be in the range of $1.175 billion to $1.185 billion. Adjusted EBITDA is predictable to be in the range of $75 million to $85 million. Adjusted EBITDA excludes forecasted stock-based compensation expense of about $112 million and forecasted depreciation and amortization expense of about $22 million and assumes minimal provision for income taxes given our net loss position. Diluted shares outstanding for the full year 2015 are predictable to be about 221 million.
Pandora Media, Inc. provides Internet radio services in the United States. The company allows listeners to create up to 100 personalized stations to access free music and comedy catalogs, in addition to offers Pandora One, a paid subscription service to listeners.
Shares of Bristol-Myers Squibb Company (NYSE:BMY), declined -3.31% to $65.98, during its last trading session.
Bristol-Myers Squibb Company declared that the European Medicines Agency (EMA) has validated two of the company’s type II variation applications, which seek to extend the current indication for its Immuno-Oncology agent, Opdivo. Validation of the applications confirms that the submissions are complete and starts the EMA’s centralized review process.
In lung cancer, the projected new indication addresses the non-squamous NSCLC population — Opdivo as monotherapy for the treatment of locally advanced or metastatic non-squamous NSCLC after preceding chemotherapy in adults. In melanoma, the projected new indication aims to extend the use of Opdivo monotherapy to its use in combination — Opdivo in combination with Yervoy for the treatment of advanced (unresectable or metastatic) melanoma in adults.
“The starting of the EMA’s centralized review process marks a noteworthy milestone in our commitment to make Opdivo accessible for a broader range of appropriate patients with advanced melanoma and lung cancer in Europe,” said Michael Giordano, M.D., senior vice president, head of Oncology Development, Bristol-Myers Squibb. “Today’s declaration also is a step forward in realizing our vision to change survival expectations, transform the standard of cancer care, and the way patients live with cancer across multiple tumor types. We look forward to working with the EMA during its review process.”
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, New Senior Investment Group Inc. (NYSE:SNR), ended its last trade with -2.23% loss, and closed at $12.74, hitting its lowest level.
New Senior Investment Group declared recently that it will release its second quarter 2015 financial results on Thursday, August 6, 2015 preceding to the opening of trading on the New York Stock Exchange.
In addition, administration will host a conference call on August 6, 2015 at 9:00 A.M. Eastern Time. The conference call may be accessed by dialing (855) 734-8393 (from within the U.S.) or (970) 315-0985 (from outside of the U.S.) ten minutes preceding to the planned start of the call; please reference “New Senior Second Quarter Earnings Call.”
New Senior Investment Group Inc. (NYSE:SNR.WI) operates independently of Newcastle Investment Corp. as of November 6, 2014.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
